I hope everyone read my positive write-up yesterday of Exact Sciences (EXAS) and its revamped stool-based gene test for colon cancer. Amazing, I know, but I am capable of being bullish on a healthcare stock. I sincerely think Exact is a compelling turnaround story.
Of course, even my positive columns get pushback. Rick A. doesn't think Exact's efforts to improve its stool-based test will matter much because patients still don't want to deal with their stool.
"I'm sorry, but compliance is the thing with colon cancer screening. Exact could have the best science in the world but if patients won't bring in their stool test kits (and they won't) nothing is gained. With a blood test, docs actually get near perfect compliance... as in 'I'm going to draw a little blood from you.' The patient goes 'OK.' It'll be just one more test on the panel. "
Enzo Biochem (ENZ) recently signed a deal with GeneNews of Canada to bring their blood-based colon cancer screening test to the U.S. the second half of this year...For me, getting patients to cooperate is 90% of taking care of them. It's amazing how they'll sit still while I stick them, but they won't play with their poop even if it will potentially save their life."I agree that a blood-based molecular screen would be vastly preferred over one in which patients have to "play with their poop," even if just a little. I'm not familiar with the Enzo-GeneNews test, but I was under the impression that blood-based tests, to date, have not demonstrated sufficient accuracy in detecting important pre-cancerous lesions in the colon. That's something that Exact's stool-based test can do.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV